-+ 0.00%
-+ 0.00%
-+ 0.00%

BIOCRYST PHARMACEUTICALS - ESTIMATES $6.2-$7.50 MLN IN ONE-TIME EXPENSES FOR TERMINATION BENEFITS, $5.3-$6.60 MLN CASH - SEC FILING

Reuters·08/04/2026 11:17:51

Please log in to view news